Business Wire

NJ-KOLMAR-KOREA

16.7.2024 15:01:28 CEST | Business Wire | Press release

Share
Kolmar Korea Appoints Global Experts to Speed up Its Presence in North America

Kolmar Korea (KRX: 161890) is speeding up its global expansion by appointing experts in the global cosmetics industry to its North American subsidiary. With the plan to build its second U.S. plant early next year, the company has appointed a new head for its North American operations and a Global Chief Commercial Officer (GCCO). It has also set up a strategic framework that integrates production, sales, and R&D to better penetrate the local market. This plan includes creating an R&D team for North America and appointing a new manager.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716576189/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kolmar USA 2nd plant (Photo: Kolmar Korea)

Kolmar Korea announced that it has named President Yongchul Hur as CEO of Kolmar Laboratories and Kolmar USA, its North American subsidiaries. Philippe Warnery has been appointed as Global Chief Commercial Officer (GCCO), George Rivera as Chief Science Officer (CSO) of the North American subsidiary, and Managing Director Inki Park as head of the R&D Center for North America, responsible for bridging the Korean and North American markets.

The key part of the recent appointments is bringing in many people with vast experience in the global cosmetics market. This is expected to help the company enter the North American market successfully.

Yongchul Hur, the new CEO of Kolmar North American subsidiaries, brings a wealth of experience in the global ODM business, having overseen production of Kolmar Korea's skincare and makeup products. He has previously served as president of Kolmar Beijing and Kolmar Wuxi, driving significant growth in Kolmar's Chinese operations. Prior to his tenure at Kolmar Korea, he held prominent positions in the cosmetics manufacturing industry, including factory manager at Amore Pacific and CEO of Cosvision. President Hur intends to leverage his decades of industry experience to steer local business in North America.

Philippe Warnery, newly appointed as Global Chief Commercial Officer (GCCO), is an expert in the global cosmetics market. His prior roles include CEO of Intercos North America, an Italian cosmetics ODM, and President of the UK & Ireland Region and General Manager of the Canadian Affiliate at Estee Lauder. With 25 years of experience in the global cosmetics industry, spanning both brand companies and ODM companies, his extensive network is a key competitive advantage. Warnery aims to focus on securing significant sales from major global brands as well as indie brands and recruiting influencers that are gaining popularity worldwide.

George Rivera, appointed as Chief Science Officer (CSO) of Kolmar North American subsidiaries, is an expert with over 20 years of R&D experience at global cosmetics companies such as L'Oreal USA and Intercos. Most recently, he led process and technology innovation as president of Kolmar USA. CSO Rivera, in collaboration with Inki Park, head of the North American R&D Center, plans to concentrate on research and development tailored to the local market's needs.

Center Head Park, a research expert with 18 years of experience, is responsible for adapting core technologies developed at the Kolmar R&D Complex, the Kolmar Group's global R&D hub located in South Korea, to the local market. Utilizing data accumulated at the Complex, including color, formulation, and scent, Park's team will analyze the needs of overseas markets and focus on developing customized formulations.

Kolmar Korea intends to leverage this strategic hires to maximize the operational capacity of its North American production facilities, including the first U.S. plant and the second plant under construction. The company aims to achieve $100 million in sales in the next five years. To this end, it plans to aggressively expand its sales network not only in North America but also in Central and South America. Moreover, with the rising popularity of K-beauty in the U.S. market through global distribution channels such as Amazon, the company plans to actively promote ODM sales that emphasize market accessibility and logistics efficiency for small and medium-sized Korean indie brands seeking entry into the U.S. market.

A representative of Kolmar Korea stated, “This appointment underscores our commitment to gaining new momentum in the North American market by placing industry experts at the forefront. Kolmar Korea will focus on fostering growth through the synergistic collaboration of sales, production, and R&D and expanding its influence beyond North America to Europe."

Understanding the importance of the North American market, Kolmar Korea has acquired Kolmar USA (formerly known as PTP) and Kolmar Canada (formerly known as CSR) in 2016 preemptively establishing a foundation for global expansion. In 2022, Kolmar Korea acquired 100% of the ‘Kolmar’ brand trademark rights, securing exclusive rights to the brand and enabling unrestricted business operations in the U.S. and global markets. The company is expanding its sales network with the recent opening of the Kolmar Innovation Center in New Jersey, USA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716576189/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye